All Updates

All Updates

icon
Filter
Partnerships
Illumina and Pillar Biosciences partner to enhance personalized cancer treatment
Precision Medicine
Jul 25, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Jul 25, 2023

Illumina and Pillar Biosciences partner to enhance personalized cancer treatment

Partnerships

  • Leading genetic testing company Illumina and next-generation sequencing (NGS) testing company Pillar Biosciences have formed a strategic partnership to make Pillar's suite of oncology assays globally available as part of Illumina's portfolio of oncology products.

  • The partnership allows the integration of Pillar's targeted sequencing technology with Illumina's advanced sequencing and bioinformatics solutions. This combination enables rapid and focused genomic profiling of tumors, aiding in personalized therapy for cancer patients.

  • The collaboration aims to enhance the efficiency, accuracy, and cost-effectiveness of oncology testing, providing patients with better access to personalized cancer treatment options. The commercial availability of Pillar's assays through Illumina is set to begin in July 2023.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.